CSL Limited
| Company type | Public |
|---|---|
| |
| Industry | Biotechnology |
| Founded | 1916 (Federal government department), 1994 (privatised) |
| Headquarters | Parkville, Melbourne, Victoria, Australia (Global), |
Key people | Paul McKenzie (CEO) |
| Products | blood plasma, vaccines, antivenom, other laboratory and medical products |
| Revenue | US$14.8 billion (2024) |
| US$2.91 billion (2024) | |
Number of employees | 32,000 (2024) |
| Divisions |
|
| Website | www |
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.